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Abstract
Background: Breast cancer has recently increased in post-menopausal Iraqi women. In Western countries at high-
risk for breast cancer, there is a bimodal increase in estrogen receptor (ER) positive tumors with a peak of low
proliferation rate luminal A over higher proliferation rate luminal B tumors after 60 years of age. The aim of this
study was to analyze in Iraqi women whether shifts are occurring in immunohistochemical (IHC) surrogates of
molecular breast cancer subtypes toward a high-risk profile.
Methods: Age specific and age standardized womens breast cancer incidence was estimated for the years 2006
through 2012. IHC results of ER, PR, HER2, and Ki67 testing were analyzed on the breast cancers of 125 Arabic and
725 Kurdish women by frequency of distribution and by age.
Results: Between 2006 and 2012, age standardized incidence of breast cancer in Iraq increased from 30 to 40/
100,000 women with the increase specifically occurring in women ≥ 60 years old (P < 0.001). Breast cancers in
Kurdish women ≥ 60 years old may also have increased (P = 0.047) with urban exceeding rural rates by 2:1. For both
Kurdish and Arabic women, there was a marked predominance of luminal B tumors at all ages in which luminal B
and luminal A tumors were asymmetric skewed toward older age but with no late luminal A age peak.
Conclusions: Older Iraqi women do not show the bimodal shift toward higher rates of luminal A breast cancers
seen in the West. The modest increase in age standardized incidence of breast cancer in Iraqi is being seen
specifically in older women and may be better attributed to a trend for care in urban cancer centers rather than
changing tumor characteristics.
Keywords: Breast cancer, Iraq, Cancer incidence, Breast cancer receptors, Luminal A and luminal B breast cancer,
Middle-East
Background
In the developing world, cancer is projected to increase by
70% over the next 20–25 years. Breast cancer represents
20–30% of cancer among women and is likely to account
for a major part of that increase [1]. These expectations
are anticipated because the populations of developing
countries are ageing and cancer is largely a disease of
older people. Life-style changes are likely to contribute,
because transitions from a traditional to a Westernized
life-style expose women to higher individual risk [2].
The world can be divided into low-risk and high-risk re-
gions on the basis of differences in breast cancer incidence
[1, 2]. Those at high-risk consists of the developed coun-
tries of Northern Europe, North American, Uruguay,
Argentina, Australia and New Zealand. In these areas, age
standardized incidence exceeds 80-100/100,000 women.
In the developing world, age standardized incidence (ASI)
varies from 20-60/100,000 women, and in parts of Central
and Southeast Asia and sub-Saharan Africa, estimates are
less than 20/100,000 [1, 2].
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Breast cancer in all parts of the world begins to be
seen at about 20 years of age [3]. Afterward, age specific
incidence steadily rises until the menopause when geo-
graphic differences begin to be seen. In the developing
world, a flattening and then a decline occur about 10–15
years after the menopause. In developed countries, the
age specific incidence accelerates after the menopause,
and at age 70 and above doubles that seen at 45–49
years old [3–5]. The life-style changes contributing to
increased post-menopausal breast cancer are largely pre-
menopausal and include obesity, low rates of childbirth,
infrequent or no lactation, early menarche, and late
menopause [2]. These factors, that are common in high-
risk countries, promote a state of relative hyperestrogen-
ism and the development of estrogen responsive tumors
[3–5]. The life-style factors are becoming more common
in countries considered low-risk particularly in their
growing urbanized communities [6].
Molecular subtyping has defined at least four categor-
ies of breast cancer with the most prevalent type and
that being most closely related to increased estrogen ex-
posure being estrogen receptor (ER) positive and nega-
tive for the Her-2-neu (HER2) proto-oncogene [3]. ER
positive tumors are further subtyped into low prolifera-
tion rate luminal A and higher proliferation rate luminal
B tumors with the luminal A tumors being more fre-
quently seen in older women in regions of the world at
high-risk for breast cancer [3].
Breast cancer rates in Iraq and its Kurdish region were
generally stable between 2000 to 2009, but newer data
from the Iraqi Cancer Registry reveal rising rates since
2009 with women after age 50 making the major contri-
bution to the increase [5, 7–9]. In this study, demo-
graphic changes are explored together with tumor ER
and HER2 subtyping. The aim of the study was to deter-
mine whether age related shifts may be occurring in ER
and HER2 subtypes that may offer insight into potential
increases of breast cancers in culturally transitional
Middle-Eastern countries.
Methods
Calculation of age specific and age standardized
incidence
Data for the country of Iraq were obtained from the
publications of the Iraqi Cancer Registry for the years
2006 and 2012 [9, 10]. These publications provided de-
tailed information regarding the age specific incidence
rates of breast cancer and the female population of Iraq
in the 5-year age ranges from 0 to 70+ years old. The
proportions of the population in the 5 year age ranges
correspond to that published by the United Nations
Population Division (population pyramid.net).
Data for Sulaimaniyah were obtained from the Hiwa
Regional Oncology Center cancer registry. The data
collection was limited to the years before 2014 so as to
not be influenced by the large recent influx of internally
displaced persons into the Kurdish region. Breast can-
cers for Sulaimaniyah were averaged for the three year
periods 2006–2008 and 2011–2013. The 2006 and 2012
Sulaimaniyah populations were obtained from the Iraqi
Cancer Registry and matched with the population esti-
mates from the Sulaimaniyah Department of Statistics.
The 5 year age distribution followed the proportions
used for all of Iraq.
For each region, age specific incidence rates were cal-
culated on the basis of the number of cancers per
100,000 women in the specified age ranges. Age stan-
dardized incidence rates were calculated using the WHO
World Standard population.
Analysis of breast cancer subtypes
Immunohistochemistry (IHC) for ER, progesterone (PR),
HER2, Ki67, and HER2 FISH for IHC equivocal HER2
cases was performed for breast cancers of Hiwa Hospital
patients at the Shorsh Hospital Pathology Department.
Details of the technical procedures have been previously
published [5]. The luminal A subtype was defined as ER
+/HER2- with a KI67 index ≤20% and PR+ with an
Allred PR score ≥ 4; the luminal B subtype was defined
as an ER+ and/or PR+ tumor, ± HER2+, and with a Ki67
index > 20% [11–14].
Statistical methods
Data was entered into an Excel worksheet and analyzed
with Stata IC10™ (Stata Corp, College Station, TX) and
SigmaStat 3.5 (Systat Software Inc., San Jose, CA) statis-
tical software. Changes in breast cancer incidence in the
years 2001 to 2012 were analyzed by Poisson’s regression
for the age ranges 20–39, 40–49, 50–59, and 60+ years
old [15]. Differences between groups were tested by
Kruskall-Wallace analysis of variance (ANOVA) on
ranks with Dunn’s post-hoc pairwise tests. Age by ethni-
city was normally distributed for some receptor subtypes
but not others, and two-way comparisons used Wil-
coxon rank-sum tests. For all statistical procedures P <
0.05 was considered significant.
Results
Age distribution of Iraqi and Sulaimaniyah populations
The Sulaimaniyah population estimates and incidence
rates are for ethnic Kurdish women only. Table 1 speci-
fies in 5-year age ranges the raw data for female popula-
tions and the numbers of women’s breast cancers for the
years 2001, 2006, and 2012 for Iraq. There is no data
available for Sulaimaniyah in 2001, and only 2006 and
2012 are shown.
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Age standardized and age specific incidence
Table 2 demonstrates the age specific incidence rates in
the regions and the changes over the period from 2001
to 2012. Prior to 2012, the age standardized rates were
approximately 30 per 100,000 women with a peak age
specific incidence at 50–54 years old and a declining rate
in older age groups. At 70+ years old, rates were similar
to those seen at 35–39 years of age. In all of Iraq in
2012, age specific incidence exceeded 110/100,000 for all
5-year age groups from 50 to 70+ years old, and the age
standardized rate increased to 40/100,000. In Sulaima-
niyah, age standardized incidence increased slightly from
32 to 36/100,000 between 2006 and 2012.
Distribution of breast cancer by age
By Poissons regression, in all of Iraq over the decade
2001–2012, there was a significantly increased breast
cancer rate between 2006 and 2012 among women ≥
60 years old (P <0.001) but not in younger age groups
(Table 3). Table 3 also indicates that for Sulaimaniyah,
breast cancer rates may also have increased in the ≥
60 year old age group (P = 0.047).
Rural vs urban differences
We attempted to look at urban vs rural differences in
breast cancer rates. Data from Baghdad were not av-
ailable. In 2011–2013, 63.1% of Sulaimaniyah breast can-
cer patients identified themselves as living in the central
city (3-year average, central city 137 patients vs other
Table 1 The womens population and the numbers of breast cancers in Sulaimaniyah and all of Iraq by 5 year age groups
Sulaimaniyah Iraq
2006 2012 2001 2006 2012
pop BC pop BC pop BC pop BC pop BC
0–4 129187 0 136092 0 1843227 0 2352412 0 2365695 0
5–9 120025 0 126440 0 1586575 0 1995955 0 2192043 0
10–14 110863 0 116788 0 1423251 0 1721195 2 2024941 0
15–19 98036 0 103276 0 1259927 5 1530129 6 1800966 1
20–24 84292 1 88798 1 1119935 14 1312396 18 1551925 26
25–29 69633 4 73355 4 956611 66 1125539 55 1282305 76
30–34 61387 11 64668 14 816619 121 953623 136 1129203 203
35–39 55890 21 58877 19 583300 244 794087 272 1026864 355
40–44 48560 28 51155 41 466640 334 638097 388 884658 610
45–49 40314 30 42469 37 419976 386 514935 412 738741 677
50–54 28403 28 29921 28 279984 345 399765 441 522486 582
55–59 21989 26 23165 26 233320 201 310221 262 403572 481
60–64 19241 11 20269 18 209988 175 228969 214 358341 426
65–69 10995 11 11582 12 193324 107 166953 141 205681 252
70+ 16492 9 17373 15 256652 122 272958 155 300103 333
Legend: The breast cancers for Sulaimaniyah represent the averages for the three year periods 2006–2008 and 2010–2013. For Iraq, the numbers are for the
indicated year. The year is designated by the availability of population data within the period that the breast cancers were enumerated. Abbreviations:
Pop,population, BC breast cancer
Table 2 Age specific incidence per 100,000 women in five-year
age groups for Sulaimaniyah and all of Iraq for the indicated
years
Sulaimaniyah Iraq
Age (yrs) 2006 2012 2001 2006 2012
0–4 0 0 0 0 0
5–9 0 0 0 0 0
10–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 1 2 1 1 2
25–29 6 6 7 5 6
30–34 18 22 15 14 18
35–39 38 32 42 34 35
40–44 57 81 72 61 69
45–49 74 88 92 80 92
50–54 99 95 123 110 111
55–59 117 113 86 85 119
60–64 56 89 83 94 119
65–69 103 103 66 85 123
70+ 56 84 48 57 111
Total rate 32 36 33 32 40
Legend: Rates are rounded to the nearest whole number. The total rate is age
standardized using the WHO world standard population (2002)
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governate 80 patients). In 2012, the central city of Sulai-
maniyah was estimated to have a population of 867,000
(433,500 women) (www.theodora.com/wfbcurrent/iraq/
iraq_people.html). This would provide a crude incidence
of 31.6/100,000 for the central city and 15.0/100,000 for
women from the outlying areas of the Governate.
Breast cancer subtypes by age and ethnicity
In the years 2011–2013, 850 primary breast cancers
from Hiwa Hospital patients (725 Kurdish and 125
Arabic) were analyzed. The average age of Kurdish pa-
tients was 48.9 ± 11.9 and Arabic patients 49.3 ±
11.5 years, a not significant difference (P = 0.72). For
Kurdish and Arabic patients combined, the distribution
by ER+/HER2-, ER+/HER2+, ER-/HER2+, triple nega-
tive, and luminal A and luminal B subtypes in the age
ranges 20–39, 40–49, 50–59, and 60+ years old are
shown in Table 4. The great majority of tumors were ER
+/HER2- (64.8%) but with the luminal A cancers repre-
senting just 27.4% and luminal B nearly twice that num-
ber at 46.8% of subtypes. Triple negative comprised
12.8% and ER-/HER2+ 13.0% of tumors. Figures 1 and 2
are kernel density plots by age for the major subtypes.
Figure 1 reveals an earlier onset of ER+/HER2+ (luminal
A/HER+) and triple negative compared to ER+/HER2-
and ER-/HER2+ tumors. ER+/HER2- tumors showed a
pronounced skew into older age, but all subtypes over-
lapped with no significant differences in age between pa-
tients with ER+/HER2-, ER-/HER2+, and triple negative
tumors (ANOVA, P > 0.05). The proportional diagno-
ses of receptor types by Kurdish or Arab ethnicity
were not significantly different (ER+/HER2-, 457 vs
85; ER+/HER2+, 68 vs 11; ER-/HER2+, 98 vs 11;
triple-, 90 vs 17; X2 = 2.40, P = 0.49), and ethnicity ver-
sus age was not statistically different for any receptor
type (Table 5).
Age and ethnic distribution of luminal A and luminal B
tumors
Figure 2 shows that luminal B/HER2- tumors began to
be seen at an earlier age than Luminal A tumors, but
both subtypes were closely nested over the entire range
of young to old age with no suggestion of a late luminal
A peak. Luminal B/HER2+ tumors had a significantly
earlier peak than the other subtypes (P < 0.01). Al-
though Luminal B/HER2+ tumors represented only
28% of all luminal B tumors, the earlier age contributed
to all luminal B tumors being found at a significantly
earlier age than luminal A tumors (P = 0.04) but with
no significant difference in age between luminal A and
luminal B/HER2- tumors (P = 0.19). Figure 3 plots age
specific incidence per 100,000 women for the major
subtypes. The peak incidence of all cancers was about
60 years of age but then declined markedly from 60 to
80 years old. The decline includes luminal A and lu-
minal B subtypes with the incidence of luminal B ex-
ceeding that of luminal A at all ages (Fig. 4).
Table 3 Poisson regression analysis of the changes in age specific incidence rates in the indicated age ranges over the period from
2001 to 2012 in all of Iraq and over the period 2006 to 2012 for Sulaimaniyah
Sulaimaniyah Iraq
Age (years) coefficient P coefficient P
20–39 0.000 (−0.148 to 0.148) 1.000 0.000 (−0.078 to 0.078) 1.000
40–49 0.051 (−0.013 to 0.116) 0.12 −0.003 (−0.034 to 0.029) 0. 87
50–59 −0.008 (−0.062 to 0.046) 0.78 0.008 (−0.018 to 0.035) 0.54
60+ 0.064 (0.001 to 0.128) 0.047 0.063 (0.032 to 0.094) <0.001
Table 4 Sulaimaniyah ER and HER2 breast cancer subtypes by age groups, Kurdish and Arabic
Age (years) ER+/HER2- ER+/HER2+ ER-/HER2+ Triple- Luminal A Luminal B
20–39 97 19 30 28 23 67
40–49 189 33 30 31 64 96
50–59 146 18 27 26 39 57
60+ 110 9 22 22 30 48
All (%) 542 (64.8) 79 (9.4) 109 (13.0) 107 (12.8) 156 (27.4)* 268 (46.8)*
Ave age 49.7 ± 11.7 46.2 ± 11.0a 47.3 ± 10.4 48.8 ± 13.2 49.7 ± 10.7b 47.6 ± 11.3
Ki67 26.1 ± 18.6 c 39.9 ± 21.0 43.1 ± 23.0 56.6 ± 26.5 c 11.6 ± 5.0 37.9 ± 18.4
Legend: *Luminal A and luminal B are derived from ER+/HER2- and ER+/HER2+ tumors that had Ki67 testing with the percentages being extrapolated to the sum
of all subtypes. The number of luminal A and Luminal B tumors (n = 424) does not correspond to the number of ER+/HER2- and ER+/HER2+ tumors (n = 621),
because not all of the later had Ki67 testing. The age of ER+/HER2+ patients is significantly different than ER+/HER2- patients (P < 0.01)a. The age of luminal A
patients is significantly different than luminal B patients (P = 0.04)b. The Ki67 of ER+/HER2- and triple- breast cancers are significantly different than other
subtypes (P < 0.001)c
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Discussion
Molecular breast cancer subtyping is widely used clinically
to identify patients at low risk for metastasis and can be
roughly inferred on the basis of IHC testing [12, 13].
While the 2015 St Gallen’s consensus considered the IHC
designation of molecular subtypes as being impractical for
guiding treatment, the assignment may be valuable from
an epidemiologic standpoint [3, 13]. In the West, the aver-
age age of newly diagnosed breast cancer patients is >
60 years old, and the high rates of breast cancer are the re-
sult of a several-fold increase in the age specific incidence
of ER+/HER2- tumors in post-menopausal women [3–5].
In US women, on the basis of IHC with parallel
PAM50 molecular testing, luminal B breast cancers were
found to be more common than luminal A tumors by a
factor of 2.48 under 40 years of age with the ratio de-
creasing to 1.27 at 40–49 years old [16]. At 50–59 years
of age, the proportions reached parity, and at > 60 years
old, luminal A exceeded luminal B tumors by 25-50%
[16]. In terms of age specific density, this created a bi-
modal frequency for ER+ tumors in which there is a
minor peak mainly of luminal B tumors at about age 50
and a major peak due to the late contribution of luminal
A tumors near age 70 [3].
This is not seen in Sulaimaniyah for Kurdish or Arab
breast cancer patients where the average is < 50 years
old for both ethnic groups. In these Iraqi patients, lu-
minal B tumors were the predominant subtype from the
beginning of breast cancer development in the early 20s
and remained predominant at all later ages. The age dis-
tribution of both luminal A and luminal B tumors was
unimodal and closely overlapping with no suggestion of
a late peak for ER+ tumors.
On the basis of both molecular testing and IHC surro-
gates, this greater proportion of luminal B over luminal
A breast cancers has been observed in other low
Fig. 2 Kernal density plots of ER+ tumors separated into luminal B
HER2+, luminal B HER-, and luminal A tumors
Legend: Luminal B/HER2+ tumors developed first at a significantly
earlier age than luminal A tumors (P < 0.01). Luminal B/HER2- were
found next, but the age distribution was not significantly different
than for luminal A tumors (P = 0.19)
Table 5 Comparison of Arab and Kurdish ethnicity versus age
for the specified breast cancer receptor types
Receptor type Arab (n) Kurdish (n) P
ER+/HER2- 48.3 ± 10.5 (85) 49.0 ± 11.1 (457) 0.83
ER+/HER2+ 48.7 ± 10.5 (11) 44.9 ± 10.8 (79) 0.61
ER-/HER2+ 51.2 ± 7.8 (11) 1.2 ± 10.9 (98) 0.91
Triple- 53.7 ± 18.2 (17) 50.7 ± 12.1 (90) 0.81
Luminal A 51.7 ± 11.9 (15) 49.5 ± 10.6 (141) 0.53
Luminal B 46.8 ± 11.2 (31) 47.7 ± 11.4 (237) 0.66
Legend: Values are displayed as mean ± standard deviation. Comparisons are
made by Wilcoxon rank sum tests. The receptor subtypes by age were not
significantly different between Kurdish or Arabic women
Fig. 3 Age specific incidence of the four major ER and HER2
subtypes
Legend: Polynomial regression plots show a peak incidence
predominantly of ER+/HER2- tumors at approximately age 55–60
years that rapidly declines afterward
Fig. 1 Kernal density plots for the four major ER and HER2 subtypes
Legend: ER+/HER2+ tumors peak at a significantly earlier age than
ER+/HER2- tumors (P < 0.01). There is no significant difference in the
age distribution of other subtypes (ANOVA, P > 0.05)
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incidence countries, including Colombia [age standard-
ized incidence (ASI), 39.7] and China (ASI, 31.7) [17–19].
In reports of Middle-Eastern patients in which luminal A
were distinguished from ER+/PR+ luminal B tumors on the
basis of a low Ki67 index, a > 3:1 predominance of luminal
B over luminal A was found in Saudi Arabia (ASI, 24.7)
and in Moroccan Arab immigrants to Belgium [20, 21]. In
the Belgium study, Moroccan and European women were
compared [21]. The mean age of Moroccan women was 49
± 11 years old. European women who averaged 60 years old
showed a contrasting all age parity in the proportion of
luminal A and B tumors.
A 2013 report from Jordan showed that despite an in-
creasing incidence of breast cancer in older women, the
median age of all Jordanian breast cancer patients was
still 50 years old [22]. The authors claimed a predomin-
ance of luminal A tumors, but the cancers were not
identified as luminal A based upon the St. Gallen’s
guidelines and included all luminal subtypes except
those that were HER2 positive [22].
The 2013 St Galen’s guidelines recommended that lu-
minal A be defined as ER+/PR+/HER2- tumors with a
Ki67 index ≤ 14% and PR expression in > 20% of cells
[12]. Higher proliferation rate ER+ tumors including the
triple positive ER+/PR+/HER2+ subtype are considered
luminal B. The 2015 guidelines suggested a Ki67 index ≤
20% or a Ki67 index less than the laboratory average for
ER+/HER2- tumors [13]. Regardless of the specific Ki67
criteria, a low proliferation rate is needed to reasonably
replicate a luminal A molecular phenotype.
In Sulaimaniyah patients, triple negative and ER-/
HER2+ were nearly evenly distributed throughout all age
groups at a frequency approximately half that of luminal
A tumors. This is representative of triple negative and
ER-/HER2+ subtypes in other low incidence countries
and illustrates their relatively low contribution to the
total breast cancer burden compared to luminal tumors
[5, 18, 19, 23, 24]. Triple negative tumors are unusually
common in sub-Saharan and African American women
[3, 24, 25]. However, in other racial groups they seem to
have a relatively constant frequency of about 10-15%
and increase proportionately across all ages as the gen-
eral rate of breast cancer rises [3, 5, 17–19, 24–26].
The relatively higher rates of luminal B breast cancers in
developing countries may be a reflection of the younger
populations and the relatively small proportions of aging
women exposed to premenopausal hyperestrogenism. We
have previously reported that the age specific incidence of
the common ER+/HER2- breast cancer is similar in Kurdish
and US women under 50 years old [5]. The difference in the
two populations is the absence in Kurdistan of the marked
increase in the rates of ER+/HER2- tumors in older women
that is seen in the US [5]. This lends credibility to a concept
of a prolonged population exposure being needed for the
development of luminal A tumors. Nevertheless, it is worth
mentioning that the age of the population by itself is not the
determining factor. China has a huge, aging population but
a low breast cancer age standardized rate and low rates of
luminal A tumors [17, 23]. In addition, low parity, that is
considered a risk factor for post-menopausal tumors in the
West, has been public policy in China for decades.
Our findings show that breast cancer incidence was
essentially the same in the Kurdish region and in the
south of Iraq before 2010 with an age standardized rate
of approximately 30 per 100,000 women. After 2009,
rates increased to 40.0/100,000 women in the south of
Iraq and with a smaller change in Sulaimaniyah. This
seems to be following the pattern observed over the past
decade in Jordan (ASI, 53.8), Lebanon (ASI, 55.4), and
several Gulf States including Kuwait (ASI, 48.0) and
Qatar (ASI, 45.0) and may be an early phase in the tran-
sition toward higher breast cancer rates [2].
It is not obvious whether the increasing age standard-
ized rate of breast cancer in Iraq and other Middle-
Eastern countries is a true biological transition or
whether it reflects the increased utilization of urban
cancer centers [5, 19, 26, 27]. With a more general
awareness of breast cancer, financially able women may
selectively be traveling for a level of care that is not
within the means of many families. In 2011, 60.1% of
breast cancer among Jordanian women was diagnosed in
Amman where the crude incidence rate was 47.8/
100,000 [28]. This compared with the outlying Gover-
nates where crude incidence varied from 11.7 to 22.7/
100,000 women. In the Sulaimaniyah Governate, a simi-
lar clustering of breast cancer diagnosis was found in
central Sulaimaniyah city. This may indicate urban/rural
differences in incidence but as likely represents patterns
of accessing cancer care.
Fig. 4 Age specific incidence of luminal A and luminal B tumors
Legend: Polynomial regression plots showing a predominance of
luminal B at all ages over luminal A tumors. There is no late luminal
A peak that exceeds the incidence of luminal B tumors
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The technology and specialization needed for mod-
ern cancer care necessitates its centralization but also
has the potential for creating demographic artifacts.
With mammography and MRI, central facilities have
the ability to detect small and in-situ breast cancer
that may not be found by clinical practice outside of
major centers. In addition, women taking advantage
of these facilities may be more likely to have risk fac-
tors associated with post-menopausal disease.
In many if not most Middle-East countries, luminal sub-
types represent more than 60% of breast cancers of all
ages and more than 70% after age 60 [5, 6, 20–22, 26, 27].
Whether the pattern of increasing rates of breast cancer
in older patients is taking a direction that will resemble
the West remains to be seen, and it will be valuable to
understand the relationships between cancer subtypes in
the region. If the Western pattern is followed, age stan-
dardized rate should continue to rise, the average age of
breast cancer patients should increase, and luminal A
should exceed the frequency of luminal B tumors at
around 60–70 years of age.
Conclusions
Older Iraqi women do not show the bimodal shift
toward higher rates of luminal A breast cancers seen
in the West. The modestly increased breast cancer
rates being seen in some Middle-Eastern countries
may be the result of factors different from those
occurring in the West and may not represent a tran-
sition to high-risk breast cancer rates. As an epi-
demiological study, the major limitation is that the
design is observational and retrospective and that
breast cancer subtyping is lacking in Iraq outside of
the Kurdish region.
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